Published on 6 Dec 2021 on Zacks via Yahoo Finance
Bristol Myers Squibb BMY recently announced that the FDA has accepted for priority review the supplemental biologics license application (sBLA) for Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent.
The sBLA is seeking label expansion of the drug for the treatment of anemia in adults with non-transfusion dependent (NTD) beta thalassemia.
The FDA has set a target action date of Mar 27, 2022.